Rocket Lab stock is volatile, but that kind of comes with the territory when investing in unprofitable start-up stocks that are hard to value on the earnings-that-they-don't-have-yet.

Rocket Lab stock is volatile, but that kind of comes with the territory when investing in unprofitable start-up stocks that are hard to value on the earnings-that-they-don't-have-yet.

Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug.

The pharmaceutical giant dished out an up-front payment of $1.25 billion, with potential clinical and regulatory milestones of up to $4.8 billion for 3SBio, not including royalties.

Chime’s stock soars in its debut, to extend the streak of IPOs that have witnessed strong investor demand.

Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotech company focused on developing gene-editing therapies using CRISPR technology to treat genetic disorders by modifying patients ...

High-definition pictures of a World War I-era U.S. Navy submarine that sank to the bottom of the ocean near San Diego were just released, over a century after it was lost at sea.

The Justice Department is making a push to disrupt the schemes, which use social media to find buyers for risky stocks.